What are we looking for?
To foster the translation of ideas into innovation we are looking for novel drug targets as a basis for the development of new therapeutic approaches.
With this initiative, Bayer Schering Pharma aims to encourage research on novel targets in areas of mutual interest. By combining expertise from industry and academia we intend to accelerate the transition from basic research to new promising treatment options.
We are interested in novel targets in the fields of
Bayer Schering Pharma’s definition of a drug target:
We define a “drugable” target as a gene/protein that is amenable to modulation by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in the disease by relevant in vitro or in vivo models.
The current call for proposals is limited to the above-mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the above-mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets. Examples of successful drugable targets have been found in particular in the following target classes: enzymes (e.g. kinases, proteases), transmembrane proteins, GPCRs and other receptors, secreted proteins, and growth factors.
With this initiative, Bayer Schering Pharma aims to encourage research on novel targets in areas of mutual interest. By combining expertise from industry and academia we intend to accelerate the transition from basic research to new promising treatment options.
We are interested in novel targets in the fields of
-
Oncology
focusing on anti-angiogenic, anti-tumor and selective anti-proliferative therapies for solid tumors. -
Cardiology
focusing on novel approaches to the care of chronic and/or acute pulmonary hypertension, atrial fibrillation, heart failure, acute coronary syndrome, ischemic stroke, peripheral arterial occlusive disease, disseminated intravascular coagulation, acute lung injury/adult respiratory distress syndrome, and cardioprotection. -
Gynecology
focusing on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna) and uterine fibroids (uterine leiomyoma). -
In vivo Imaging
focusing on oncology (early diagnosis and staging, early therapy response, predictive stratification of patients) and CNS (Alzheimer’s disease, other forms of dementia, neuroinflammation), using positron emission tomography (PET) as modality.
Bayer Schering Pharma’s definition of a drug target:
We define a “drugable” target as a gene/protein that is amenable to modulation by a drug. The drug can be a small-molecular-weight chemical compound or a biological, such as an antibody or a recombinant protein. The target should have been shown to be effective/mechanistically involved in the disease by relevant in vitro or in vivo models.
The current call for proposals is limited to the above-mentioned indications, treatment paradigms and approaches (small-molecular-weight compounds, antibodies, recombinant proteins). In this call we will not fund proposals with approaches outside the above-mentioned areas, e.g. in gene or cell therapy, vaccination or unspecific approaches without defined molecular targets. Examples of successful drugable targets have been found in particular in the following target classes: enzymes (e.g. kinases, proteases), transmembrane proteins, GPCRs and other receptors, secreted proteins, and growth factors.